I 
117TH CONGRESS 
1ST SESSION H. R. 1873 
To educate health care providers and the public on biosimilar biological 
products, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 12, 2021 
Mr. BUCSHON (for himself and Mr. PETERS) introduced the following bill; 
which was referred to the Committee on Energy and Commerce 
A BILL 
To educate health care providers and the public on biosimilar 
biological products, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Advancing Education 
on Biosimilars Act of 2021’’. 
SEC. 2. EDUCATION ON BIOLOGICAL PRODUCTS. 
Subpart 1 of part F of title III of the Public Health 
Service Act (42 U.S.C. 262 et seq.) is amended by adding 
at the end the following: 
VerDate Sep 11 2014 
21:12 May 11, 2021
Jkt 019200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H1873.IH
H1873
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(C) an explanation of the process for re-
porting adverse events for biological products, 
including biosimilar biological products and 
interchangeable biosimilar biological products; 
and 
‘‘(D) an explanation of the relationship be-
tween biosimilar biological products and inter-
changeable biosimilar biological products li-
censed under section 351(k) and reference 
products (as defined in section 351(i)), includ-
ing the standards for review and licensing of 
each such type of biological product. 
‘‘(3) FORMAT.—The educational materials pro-
vided under paragraph (1) may be— 
‘‘(A) in formats such as webinars, con-
tinuing education modules, videos, fact sheets, 
infographics, stakeholder toolkits, or other for-
mats as appropriate and applicable; and 
‘‘(B) tailored for the unique needs of 
health care providers, patients, caregivers, and 
other audiences, as the Secretary determines 
appropriate. 
‘‘(4) OTHER INFORMATION.—In addition to the 
information described in paragraph (2), the Sec-
retary shall continue to publish— 
VerDate Sep 11 2014 
21:12 May 11, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1873.IH
H1873
pamtmann on DSKBC07HB2PROD with BILLS
‘‘(A) the action package of each biological 
product licensed under subsection (a) or (k) of 
section 351; or 
‘‘(B) the summary review of each biological 
product licensed under subsection (a) or (k) of 
section 351. 
‘‘(5) CONFIDENTIAL AND TRADE SECRET IN-
FORMATION.—This subsection does not authorize 
the disclosure of any trade secret, confidential com-
mercial or financial information, or other matter de-
scribed in section 552(b) of title 5. 
‘‘(b) CONTINUING EDUCATION.—The Secretary shall 
advance education and awareness among health care pro-
viders regarding biological products, including biosimilar 
biological products and interchangeable biosimilar biologi-
cal products, as appropriate, including by developing or 
improving continuing education programs that advance 
the education of such providers on the prescribing of, and 
relevant clinical considerations with respect to, biological 
products, including biosimilar biological products and 
interchangeable biosimilar biological products.’’. 
Æ 
VerDate Sep 11 2014 
21:12 May 11, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H1873.IH
H1873
pamtmann on DSKBC07HB2PROD with BILLS